Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment
Sarah A Best, David P De Souza, Ariena Kersbergen, Antonia N Policheni, Saravanan Dayalan, Dedreia Tull, Vivek Rathi, Daniel H Gray, Matthew E Ritchie, Malcolm J McConville, Kate D Sutherland
Cell Metabolism | CELL PRESS | Published : 2018
Awarded by Worldwide Cancer Research Project grant
Awarded by Australian Health and Medical Research Council (NHMRC)
Awarded by Victorian Cancer Agency (VCA) Early Career Seed Grant
We are grateful to C. Alvarado, L. Scott, K. Birchall, and L. Mackiewicz for animal husbandry; S. Monard for flow cytometry assistance; E. Tsui and C. Tsui in the WEHI Histology Facility for expert support; S. Carpineteri, C. Bowen (Shimadzu Australia), and V. Narayana (Metabolomics Australia) for technical assistance; and L. O'Rielly for CD8 antibody. We are thankful to A. Cox, J. Vissers (Peter MacCallum Cancer Centre), A. Berns, and P. Krimpenfort (Netherlands Cancer Institute) for critical reading of the manuscript and J. Visvader for useful discussions. This work was supported by a Worldwide Cancer Research Project grant (14-0433) and in part by an Australian Health and Medical Research Council (NHMRC) grant to K.D.S. and M.E.R. (1138275). S.A.B. is supported by a Victorian Cancer Agency (VCA) Early Career Seed Grant (ECSG16001); K.D.S. is supported by the Peter and Julie Alston Centenary Fellowship. M.J.M. is an NHMRC Principal Research Fellow. This work was made possible through Victorian Government Operational Infrastructure Support and the Australian government.